Madrigal Pharmaceuticals

Breakthrough in Liver Disease Treatments: Madrigal’s Resmetirom Aims to Be the First Approved NASH Therapy

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (NASDAQ: MDGL) recently took a significant stride towards introducing the first treatment for Nonalcoholic Steatohepatitis (NASH) with liver fibrosis. The drug, resmetirom, has cleared a …

Breakthrough in Liver Disease Treatments: Madrigal’s Resmetirom Aims to Be the First Approved NASH Therapy Read More